{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:11:58Z","timestamp":1785777118423,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T00:00:00Z","timestamp":1250640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00262-009-0750-3","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T10:57:13Z","timestamp":1250593033000},"page":"293-301","source":"Crossref","is-referenced-by-count":63,"title":["A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer"],"prefix":"10.1007","volume":"59","author":[{"given":"Anda M.","family":"Vlad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca A.","family":"Budiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana E.","family":"Lenzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Thaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Colonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Crowley-Nowick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric V.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"750_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10\u201330","journal-title":"CA Cancer J Clin"},{"key":"750_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"750_CR3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519\u20132529","journal-title":"N Engl J Med"},{"key":"750_CR4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"750_CR5","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950\u20131955","journal-title":"N Engl J Med"},{"key":"750_CR6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1998.5016","volume":"69","author":"M Markman","year":"1998","unstructured":"Markman M, Blessing JA, Moore D, Ball H, Lentz SS (1998) Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 69:226\u2013229","journal-title":"Gynecol Oncol"},{"key":"750_CR7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34\u201343","journal-title":"N Engl J Med"},{"key":"750_CR8","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485\u20131492","journal-title":"N Engl J Med"},{"key":"750_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000055359","volume":"61","author":"L Elias","year":"2001","unstructured":"Elias L, Hunt WC (2001) A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology 61:91\u2013101","journal-title":"Oncology"},{"key":"750_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cad.0000182748.47353.51","volume":"17","author":"C Grande","year":"2006","unstructured":"Grande C, Firvida JL, Navas V, Casal J (2006) Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17:1\u201312","journal-title":"Anticancer Drugs"},{"key":"750_CR11","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.1997.15.11.3399","volume":"15","author":"RP Edwards","year":"1997","unstructured":"Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisseri M, Kirkwood JM, Herberman RB (1997) Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 15:3399\u20133407","journal-title":"J Clin Oncol"},{"key":"750_CR12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1992.10.9.1479","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W (1992) Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479\u20131484","journal-title":"J Clin Oncol"},{"key":"750_CR13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105\u20132116","journal-title":"J Clin Oncol"},{"key":"750_CR14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688\u2013696","journal-title":"J Clin Oncol"},{"key":"750_CR15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.bjc.6600437","volume":"87","author":"F Donskov","year":"2002","unstructured":"Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M (2002) Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 87:194\u2013201","journal-title":"Br J Cancer"},{"key":"750_CR16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.bjc.6690371","volume":"80","author":"L Fumagalli","year":"1999","unstructured":"Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F (1999) Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80:407\u2013411","journal-title":"Br J Cancer"},{"key":"750_CR17","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.3346\/jkms.2007.22.S.S122","volume":"22","author":"IG Jeong","year":"2007","unstructured":"Jeong IG, Han KS, Joung JY, Choi WS, Hwang SS, Yang SO, Seo HK, Chung J, Lee KH (2007) Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci 22:S122\u2013S128","journal-title":"J Korean Med Sci"},{"key":"750_CR18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001\u20131007","journal-title":"J Clin Oncol"},{"key":"750_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000030473","volume":"64","author":"V Bordin","year":"2000","unstructured":"Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandala M, Paolorossi F, Ardizzoia A, Tancini G, Barni S, Frigerio F, Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Lissoni P (2000) Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol Int 64:3\u20138","journal-title":"Urol Int"},{"key":"750_CR20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000227311","volume":"51","author":"P Lissoni","year":"1994","unstructured":"Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, Scardino E, Tancini G (1994) Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51:59\u201362","journal-title":"Oncology"},{"key":"750_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/cbr.1993.8.123","volume":"8","author":"PA Palmer","year":"1993","unstructured":"Palmer PA, Atzpodien J, Philip T, Negrier S, Kirchner H, Von der Maase H, Geertsen P, Evers P, Loriaux E, Oskam R et al (1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 8:123\u2013136","journal-title":"Cancer Biother"},{"key":"750_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bjc.1993.29","volume":"67","author":"A Rohr von","year":"1993","unstructured":"von Rohr A, Ghosh AK, Thatcher N, Stern PL (1993) Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 67:163\u2013171","journal-title":"Br J Cancer"},{"key":"750_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01676706","volume":"12","author":"P Wersall","year":"1995","unstructured":"Wersall P, Mellstedt H (1995) Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol 12:69\u201377","journal-title":"Med Oncol"},{"key":"750_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00423-008-0393-4","volume":"394","author":"L Degrate","year":"2009","unstructured":"Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, Leone BE, Trezzi R, Uggeri F (2009) Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 394:115\u2013121","journal-title":"Langenbecks Arch Surg"},{"key":"750_CR25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1172\/JCI115383","volume":"88","author":"TH Rand","year":"1991","unstructured":"Rand TH, Silberstein DS, Kornfeld H, Weller PF (1991) Human eosinophils express functional interleukin 2 receptors. J Clin Invest 88:825\u2013832","journal-title":"J Clin Invest"},{"key":"750_CR26","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.159.9.4593","volume":"159","author":"B Lamkhioued","year":"1997","unstructured":"Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, Rothenberg MD, Luster AD, Hamid Q (1997) Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 159:4593\u20134601","journal-title":"J Immunol"},{"key":"750_CR27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/bbrc.1997.6958","volume":"236","author":"S Mattoli","year":"1997","unstructured":"Mattoli S, Stacey MA, Sun G, Bellini A, Marini M (1997) Eotaxin expression and eosinophilic inflammation in asthma. Biochem Biophys Res Commun 236:299\u2013301","journal-title":"Biochem Biophys Res Commun"},{"key":"750_CR28","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/eji.1830271252","volume":"27","author":"S Ying","year":"1997","unstructured":"Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB (1997) Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 27:3507\u20133516","journal-title":"Eur J Immunol"},{"key":"750_CR29","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S","volume":"88","author":"MJ Fernandez-Acenero","year":"2000","unstructured":"Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544\u20131548","journal-title":"Cancer"},{"key":"750_CR30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.2910540103","volume":"54","author":"L Rivoltini","year":"1993","unstructured":"Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G (1993) In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 54:8\u201315","journal-title":"Int J Cancer"},{"key":"750_CR31","first-page":"807","volume":"12","author":"M Samoszuk","year":"1997","unstructured":"Samoszuk M (1997) Eosinophils and human cancer. Histol Histopathol 12:807\u2013812","journal-title":"Histol Histopathol"},{"key":"750_CR32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<436::AID-CNCR3>3.0.CO;2-I","volume":"77","author":"SE Leighton","year":"1996","unstructured":"Leighton SE, Teo JG, Leung SF, Cheung AY, Lee JC, van Hasselt CA (1996) Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer 77:436\u2013440","journal-title":"Cancer"},{"key":"750_CR33","first-page":"298","volume":"85","author":"M Moroni","year":"2000","unstructured":"Moroni M, Porta C, De Amici M, Quaglini S, Cattabiani MA, Buzio C (2000) Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 85:298\u2013303","journal-title":"Haematologica"},{"key":"750_CR34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0046-8177(96)90216-6","volume":"27","author":"WJ Driel van","year":"1996","unstructured":"van Driel WJ, Hogendoorn PC, Jansen FW, Zwinderman AH, Trimbos JB, Fleuren GJ (1996) Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response. Hum Pathol 27:904\u2013911","journal-title":"Hum Pathol"},{"key":"750_CR35","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.4049\/jimmunol.179.5.2832","volume":"179","author":"SN Karagiannis","year":"2007","unstructured":"Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179:2832\u20132843","journal-title":"J Immunol"},{"key":"750_CR36","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1084\/jem.193.6.F23","volume":"193","author":"LM Coussens","year":"2001","unstructured":"Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different. J Exp Med 193:F23\u2013F26","journal-title":"J Exp Med"},{"key":"750_CR37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1245\/s10434-006-9239-x","volume":"14","author":"GC Cesana","year":"2007","unstructured":"Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F (2007) Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol 14:1295\u20131304","journal-title":"Ann Surg Oncol"},{"key":"750_CR38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00262-004-0525-9","volume":"53","author":"F Donskov","year":"2004","unstructured":"Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, Madsen HH, Fode K, von der Maase H (2004) Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53:729\u2013739","journal-title":"Cancer Immunol Immunother"},{"key":"750_CR39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2008","unstructured":"Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB (2008) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22:393\u2013402","journal-title":"Mod Pathol"},{"key":"750_CR40","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8\u00a0+\u00a0tumor-infiltrating lymphocytes and a high CD8\u00a0+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538\u201318543","journal-title":"Proc Natl Acad Sci USA"},{"key":"750_CR41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203\u2013213","journal-title":"N Engl J Med"},{"key":"750_CR42","first-page":"1515","volume":"60","author":"O Egeter","year":"2000","unstructured":"Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M (2000) Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 60:1515\u20131520","journal-title":"Cancer Res"},{"key":"750_CR43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698\u20132703","journal-title":"N Engl J Med"},{"key":"750_CR44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2008.04.001","volume":"13","author":"N Muller-Hermelink","year":"2008","unstructured":"Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507\u2013518","journal-title":"Cancer Cell"},{"key":"750_CR45","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1016\/j.vaccine.2008.06.092","volume":"26","author":"JM Grange","year":"2008","unstructured":"Grange JM, Bottasso O, Stanford CA, Stanford JL (2008) The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26:4984\u20134990","journal-title":"Vaccine"},{"key":"750_CR46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","volume":"27","author":"MP Schon","year":"2008","unstructured":"Schon MP, Schon M (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27:190\u2013199","journal-title":"Oncogene"},{"key":"750_CR47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579\u2013591","journal-title":"Nat Rev Cancer"},{"key":"750_CR48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/14737159.8.3.301","volume":"8","author":"R Longo","year":"2008","unstructured":"Longo R, Gasparini G (2008) Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn 8:301\u2013314","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-009-0750-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0750-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:05:24Z","timestamp":1685099124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0750-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0750-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,19]]}}}